Integrated Tools For Upstream Process Intensification: Part II
Changes to bioprocessing methodologies in the biopharmaceutical industry are being driven by the need for increased speed, a lower cost of goods (COGs) and greater flexibility. Faster development times are required to progress biologics and vaccines more rapidly into clinical development and then to market to improve worldwide accessibility.
For intensified processes to be scaled-up effectively, operating conditions need to be modelled accurately. To do this in competitive time frames using regular fed batch, this needs to be done in high throughput mode; in 2018, SSB introduced a new version of its ambr technology platform for intensified processing — the ambr 250 high throughput perfusion system.
Get unlimited access to:
Enter your credentials below to log in. Not yet a member of Drug Discovery Online? Subscribe today.